Information Provided By: 
Fly News Breaks for November 28, 2018
BGNE, ZYME
Nov 28, 2018 | 07:28 EDT
Canaccord analyst Arlinda Lee views Zymeworks' (ZYME) partnership with BeiGene (BGNE) as a positive as it ties in the company with a commercial-stage pharma company that has experience and a foothold in the Asia-Pacific region, where gastric cancers are more prevalent. She continues to view Zymeworks' complementary suite of "plug and play" platform technologies, particularly in its bi specific antibody platform, as attractive. Lee reiterated her Buy rating and $21 price target on Zymeworks shares.
News For ZYME;BGNE From the Last 2 Days
There are no results for your query ZYME;BGNE
